ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...

ANKTIVA, in combination with an immune checkpoint inhibitor, has received accelerated approval from the Saudi Food and Drug ...

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...

Merck has other promising candidates in its late-stage pipeline, such as enlicitide decanoate/MK-0616, an oral PCSK9 ...

Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S.

iOnctura CEO to present at the 2026 J.P. Morgan Healthcare Conference -- Participation underscores growing excitement around company's momentum and potential in precision oncology ...

Sahil Verma [email protected] For the first time in the history of Ladakh after attaining the status of a Union Territory ...

Mare BioInnovations launchd Ocythera led by Dr. Martin Petkovich with support of Dr. Don Cameron and acting CEO Joseph ...

CNW/ - adMare BioInnovations is proud to announce the creation of Ocythera, a new biopharmaceutical company dedicated to ...

M+ cash runway to 2029, bitopertin FDA NDA/accelerated approval catalyst, and DISC-0974 myelofibrosis data—read now.